United States of America v. Arriva Medical, LLC

CourtDistrict Court, M.D. Tennessee
DecidedMarch 24, 2020
Docket3:13-cv-00760
StatusUnknown

This text of United States of America v. Arriva Medical, LLC (United States of America v. Arriva Medical, LLC) is published on Counsel Stack Legal Research, covering District Court, M.D. Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States of America v. Arriva Medical, LLC, (M.D. Tenn. 2020).

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF TENNESSEE NASHVILLE DIVISION

UNITED STATE OF AMERICA ex rel. ) GREGORY M. GOODMAN, ) ) Plaintiff, ) ) v. ) Case No. 3:13-cv-0760 ) Judge Aleta A. Trauger ARRIVA MEDICAL, LLC, ALERE, INC., ) TED ALBIN, and GRAPEVINE BILLING ) AND CONSULTING SERVICES, INC., ) ) Defendants. ) )

MEMORANDUM

Ted Albin and Grapevine Professional Services, Inc. d/b/a Grapevine Billing and Consulting Services1 (“Grapevine”) have filed a Motion to Dismiss (Docket No. 128), to which the United States has filed a Response (Docket No. 134), and Albin and Grapevine have filed a Reply (Docket No. 137). For the reasons set out herein, the motion will be denied. I. BACKGROUND In 1863, “as a result of investigations of the fraudulent use of government funds during the Civil War,” Congress enacted the original version of the False Claims Act, now typically referred to as the “FCA.” United States v. Neifert-White Co., 390 U.S. 228, 232 (1968). Although “[d]ebates at the time suggest that the Act was intended to reach all types of fraud, without qualification, that might result in financial loss to the Government,” id., the Act “was originally aimed principally at stopping the massive frauds perpetrated by large contractors” related to the war effort. United

1 Grapevine contends that the corporate name attributed to it by the Government in the case caption, “Grapevine Billing and Consulting Services, Inc.,” is incorrect. (Docket No. 129 at 3 n.1.) States v. Bornstein, 423 U.S. 303, 309 (1976). The Act, in amended form, has endured for over a century and a half, in which it has witnessed generations of change in the types of fraud committed and the types of government funds vulnerable to fraud. Today, the False Claims Act is often, although far from exclusively, invoked in the context of the large public expenditures related to the nation’s various federal (or joint federal/state) healthcare programs—most prominently,

Medicare, Medicaid, and TRICARE. “Since its enactment . . . , the False Claims Act has authorized both the Attorney General and private qui tam relators to recover from persons who make false or fraudulent claims for payment to the United States.” Graham Cty. Soil & Water Conservation Dist. v. U.S. ex rel. Wilson, 559 U.S. 280, 283 (2010). The qui tam provision creates an incentive for private individuals who become aware of fraud on the government to bring that fraud to light, in exchange for a share of the recovery—which, pursuant to 31 U.S.C. § 3729(a)(1), can include both treble damages and penalties. See State Farm Fire & Cas. Co. v. U.S ex rel. Rigsby, 137 S. Ct. 436, 440 (2016) (observing that “[t]his system is designed to benefit both the relator and the Government.”). On

August 1, 2013, one such qui tam relator, Gregory M. Goodman, filed an FCA Complaint against his employer, Arriva Medical, LLC, and the company that acquired it, Alere, Inc. (Docket No. 1 ¶¶ 4, 10.) He accused the companies of “six distinct but related schemes to defraud the federal government.” (Id. ¶ 11.) Among Goodman’s allegations was that the defendants, who provide diabetes supplies such as glucose meters and test strips, improperly waived or forgave Medicare Part B patients’ copayment and deductible obligations, which the Complaint characterized as a form of kickback that would give rise to FCA liability. (Id. ¶¶ 7, 13, 41.) As the Department of Health and Human Services Office of the Inspector General (“HHS-OIG”) has explained, 42.U.S.C. § 1320a-7a(a)(5) prohibits a person from offering or transferring remuneration to a beneficiary that such person knows or should know is likely to influence the beneficiary to order items or services from a particular provider or supplier for which payment may be made under a Federal health care program. “Remuneration” is defined as including a waiver of coinsurance and deductible amounts, with exceptions for certain financial hardship waivers, which are not prohibited.

(Id. ¶ 41 (quoting HHS-OIG, Blood Glucose Test Strips: Marketing to Medicare Beneficiaries, OEI-03-98-00231 (June 2000)).) Accordingly, influencing a patient’s choice of diabetes supply vendors by waiving his copays is, the argument goes, an unlawful kickback. (Id.) Pursuant to the Anti-Kickback Statute (“AKS”), a claim for payment under a federal healthcare program “that includes items or services resulting from a violation of the” AKS’s anti-kickback provisions “constitutes a false or fraudulent claim for purposes of” the FCA. 42 U.S.C. § 1320a-7b(g). The Complaint pleaded six counts under the FCA, with each count representing a different theory of liability encompassing numerous Medicare claims over time. (Id. ¶¶ 204–52.) It also pleaded claims for unjust enrichment under Tennessee common law. (Id. ¶¶ 253–57.) In addition to the copayment/deductible waiver and forgiveness allegations, Goodman alleged that Arriva/Alere routinely billed for glucose meters that it knew were likely to be disallowed under Medicare because the program had already paid for a glucose meter for that patient in the last five years. The company would then write off most or all of the patient’s liability for the glucose meter when Medicare denied payment, resulting in another form of kickback with regard to the patient’s continued use of Arriva/Alere for other supplies. (Id. ¶¶ 68, 121.) A qui tam complaint under the FCA “shall be filed in camera, shall remain under seal for at least 60 days, and shall not be served on the defendant until the court so orders.” 31 U.S.C. § 3730(b)(2). “The Government may, for good cause shown, move the court for extensions of the time during which the complaint remains under seal . . . .” 31 U.S.C. § 3730(b)(3). Eventually, however, the Government faces a choice: it must either inform the court that it wishes to “proceed with the action, in which case” the Government will take over the litigation; or it must “notify the court that it declines to take over the action, in which case the person bringing the action shall have the right to conduct the action.” 31 U.S.C. § 3730(b)(4)(A)–(B). In the years following Goodman’s filing of his Complaint, the Government received a number of extensions of the seal and the

window for intervention, in order to allow it to pursue its investigation of the defendants. (See, e.g., Docket Nos. 21, 29, 36, 40, 44, 48, 52, 66.) For the first few years of the Government’s investigation, it apparently had no knowledge of any connection between the activities it was investigating and Albin or Grapevine, who had not yet been named as defendants. In February of 2017, however, emails to and from Albin “were produced by Arriva and Alere to the government” as part of its investigation. (Docket No. 121 ¶¶ 351–53.) The Government issued a civil investigative demand, or “CID,”2 to Albin, pursuant to which he provided testimony on April 30, 2018. (Id. ¶ 354.) During the testimony, Albin admitted that, while he had been a consultant for Arriva, he, among other things, created a policy of not

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kelly McGinley v. Gorman Houston
361 F.3d 1328 (Eleventh Circuit, 2004)
Conley v. Gibson
355 U.S. 41 (Supreme Court, 1957)
United States v. Neifert-White Co.
390 U.S. 228 (Supreme Court, 1968)
Scheuer v. Rhodes
416 U.S. 232 (Supreme Court, 1974)
United States v. Bornstein
423 U.S. 303 (Supreme Court, 1976)
Swierkiewicz v. Sorema N. A.
534 U.S. 506 (Supreme Court, 2002)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
United States v. Alemany Rivera
55 F.3d 703 (First Circuit, 1995)
Freeman Industries, LLC v. Eastman Chemical Co.
172 S.W.3d 512 (Tennessee Supreme Court, 2005)
Bishop v. Lucent Technologies, Inc.
520 F.3d 516 (Sixth Circuit, 2008)
US Ex Rel. Marlar v. Bwxt Y-12, LLC
525 F.3d 439 (Sixth Circuit, 2008)
United States Ex Rel. Snapp, Inc. v. Ford Motor Co.
532 F.3d 496 (Sixth Circuit, 2008)
United States v. Community Health Systems, Inc.
501 F.3d 493 (Sixth Circuit, 2007)
United States v. Bourseau
531 F.3d 1159 (Ninth Circuit, 2008)
United States v. Rogan
459 F. Supp. 2d 692 (N.D. Illinois, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
United States of America v. Arriva Medical, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-of-america-v-arriva-medical-llc-tnmd-2020.